Dual targeting of EGFR and HER-2 in colon cancer cell lines Efstathia GiannopoulouAnna AntonacopoulouHaralabos P. Kalofonos Original Article 27 August 2008 Pages: 973 - 981
Lack of toxicity of a STAT3 decoy oligonucleotide Malabika SenPatricia J. ToscaJennifer R. Grandis Original Article 03 September 2008 Pages: 983 - 995
Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression Hongli LiuShu-Ling LiangAimin Zhou Original Article 03 September 2008 Pages: 997 - 1005
Studies of structure–activity relationship on plant polyphenol-induced suppression of human liver cancer cells Jacky LoaPierce ChowKai Zhang Original Article 03 September 2008 Pages: 1007 - 1016
Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature Muhammad Wasif SaifJ. PeccerilloVon Potter Original Article 10 September 2008 Pages: 1017 - 1022
Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells Alexandre F. S. QueirozRodrigo A. SilvaMaurício P. de Sales Original Article 10 September 2008 Pages: 1023 - 1033
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients Jürgen B. BulittaPing ZhaoWilliam J. Jusko Original Article 13 September 2008 Pages: 1035 - 1048
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients Jürgen B. BulittaPing ZhaoWilliam J. Jusko Original Article 13 September 2008 Pages: 1049 - 1063
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors Chia-Chi LinEmiliano CalvoAnthony W. Tolcher Original Article 16 September 2008 Pages: 1065 - 1071
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies Y. XuJ. M. KolesarM. A. Villalona-Calero Original Article 16 September 2008 Pages: 1073 - 1082
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer Jae Jin LeeSi-Young KimJin-Hyuk Choi Original Article 24 September 2008 Pages: 1083 - 1090
Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer Masaru NakamuraTomonobu KoizumiNaoto Shikama Original Article 26 September 2008 Pages: 1091 - 1096
Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany Holger GerullisLothar BergmannThomas Otto Original Article 26 September 2008 Pages: 1097 - 1102
Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer Jianhui YuanHui LvZhimin He Original Article 27 September 2008 Pages: 1103 - 1110
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer Vanna Chiarion-SileniRoberto InnocenteErmanno Ancona Original Article Open access 30 September 2008 Pages: 1111 - 1119
Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines Zhenfeng DuanEdwin ChoyFrancis J. Hornicek Original Article 01 October 2008 Pages: 1121 - 1129
Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells Ze TianNing AnErxi Wu Original Article 03 October 2008 Pages: 1131 - 1139
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer Seong Yoon YiYoung Suk ParkWon Ki Kang Original Article 07 October 2008 Pages: 1141 - 1145
A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors William R. SchelmanSherry Morgan-MeadowsAnne M. Traynor Clinical Trial Report 13 December 2008 Pages: 1147 - 1156
Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab Mariantonietta ColozzaElisa MinenzaPiero Floridi Short Communication 06 November 2008 Pages: 1157 - 1159
Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose Massimo BrecciaDaniela CilloniGiuliana Alimena Short Communication 07 November 2008 Pages: 1161 - 1163
Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy Hiroshi TakaneKatsuyuki KawamotoIchiro Ieiri Short Communication 08 November 2008 Pages: 1165 - 1169
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction Gondi KumarHenry LauOscar Laskin Short Communication 23 November 2008 Pages: 1171 - 1175
Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile Cedric MercierCharlotte DupuisJoseph Ciccolini Short Communication 24 December 2008 Pages: 1177 - 1180
5-FU pretreatment potentiates cisplatin-induced apoptosis through up-regulation of thrombospondin-1 in head and neck squamous cell carcinomas Bei XuPeng Liu Letter to the Editor 04 December 2008 Pages: 1181 - 1183